Overview
SPRB market data
Price History
SPRB price chart · 1M
- O
- 62.51
- H
- 62.51
- L
- 61.64
- C
- 61.88
- Vol
- 2,705.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $62.51
- Previous Close
- $61.49
- Day High
- $62.51
- Day Low
- $61.64
- 52 Week High
- $63.97
- 52 Week Low
- $40.68
- 7 Day Return
- +15.88%
- 30 Day Return
- +47.95%
- 90 Day Return
- +25.20%
- 1 Year Return
- +10.68%
- Daily Notional Volume
- $167.4K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$50.80 Diluted earnings per share over the trailing twelve months.
- Beta
- 3.37 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -1,079.9% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $7.00 – $240.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $137M · P/B 2.19 · P/S 27.89.
Company News
Spruce Biosciences Launches MPS3BStudy.com, Online Resource For Families And Caregivers Of Children With Sanfilippo Syndrome Type BBenzinga · Aug 26, 2026, 12:07 PM
Spruce Biosciences Says It Completed Two Pre-BLA Meetings With FDA Supporting Q4 2026 BLA Submission For Tralesinidase Alfa In Sanfilippo Syndrome Type B; FDA Found CMC Comparability Strategies ReasonableBenzinga · Aug 24, 2026, 1:28 PM
Guggenheim Maintains Buy on Spruce Biosciences, Lowers Price Target to $104Benzinga · Aug 17, 2026, 1:22 PM
Citizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $144Benzinga · Aug 13, 2026, 1:58 PM
8-K filing — SPRUCE BIOSCIENCES, INC. (SPRB)SEC EDGAR · Aug 12, 2026, 1:05 PM
SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. Q2 EPS $(6.68) Misses $(5.80) EstimateBenzinga · Aug 12, 2026, 1:03 PM
Spruce Biosciences Announces $5.5M Combined Strategic Investment From Cure Sanfilippo Foundation And National MPS Society To Partially Fund TA-ERT Expanded Access Program In MPS IIIBBenzinga · Aug 12, 2026, 12:04 PM
B. Riley Securities Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $160Benzinga · Jul 13, 2026, 1:07 PM
Spruce Biosciences Joins Russell 3000 Index, Effective June 29Benzinga · Jun 29, 2026, 12:10 PM
Guggenheim Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $123Benzinga · Jun 16, 2026, 12:40 PM